Mesoblast

MESO

Melbourne, Australia· Est. 2004

mesoblast.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

MESO · Stock Price

USD 14.80+3.39 (+29.71%)

Market Cap: $1.9B

Historical price data

Market Cap: $1.9BPipeline: 41 drugs (12 Phase 3)Patents: 20Founded: 2004Employees: 100-250HQ: Melbourne, Australia

Overview

Mesoblast is a pioneering Australian biotechnology company with a mission to transform patient outcomes through its proprietary allogeneic mesenchymal lineage cell technology platform. Its key achievement is the FDA approval and commercialization of RYONCIL for pediatric steroid-refractory acute graft-versus-host disease, marking it as a first-in-class therapy. The company's strategy leverages this validated platform to expand into large market opportunities in chronic low back pain, heart failure, and other inflammatory conditions, aiming to establish a new paradigm in regenerative medicine.

Hematology/OncologyCardiovascularOrthopedicImmunology

Technology Platform

Proprietary platform for industrial-scale manufacturing of allogeneic mesenchymal lineage cells, which act as targeted biologic factories to modulate inflammation and promote tissue repair.

Pipeline

41 drugs in pipeline12 in Phase 3

Drug	Indication	Stage
Remestemcel-L + Placebo	Mesenchymal Stromal Cells	Phase 3
Remestemcel-L	Grade B Acute Graft Versus Host Disease	Phase 3
Rexlemestrocel-L + HA mixture + Saline	Degenerative Disc Disease	Phase 3
Infusion of one MPC expanded cord unit and one unexpanded co...	Acute Myelogenous Leukemia	Phase 3
Prochymal® + Placebo + Standard of Care for GVHD	Graft Versus Host Disease	Phase 3

Funding History

Total raised:$138M

PIPE$138MSurgCenter DevelopmentSep 15, 2020

IPOUndisclosedUndisclosedDec 15, 2004

Opportunities

Mesoblast has near-term blockbuster opportunities in chronic low back pain and advanced heart failure, markets each exceeding $10 billion.

The FDA approval of RYONCIL de-risks the regulatory pathway for its platform, potentially accelerating approvals in these large indications and enabling expansion into other inflammatory diseases.

Risk Factors

Key risks include potential regulatory setbacks for late-stage pipeline candidates, challenges in achieving commercial uptake and favorable reimbursement for a novel therapy class, and the ongoing need for capital raising which may dilute shareholders.

The complex mechanism of action also carries inherent clinical and scientific uncertainty.

Competitive Landscape

Mesoblast holds a first-mover advantage with the only FDA-approved mesenchymal stromal cell therapy. While competitors like Athersys and Cynata develop allogeneic MSC platforms, Mesoblast's late-stage pipeline in large markets (heart failure, back pain) and proven manufacturing scale provide significant differentiation against both cell therapy peers and standard pharmaceutical interventions.